{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T23:26:50Z","timestamp":1708990010311},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The current review highlights recent insights into direct antiviral effects by antimalarials against severe acute respiratory syndrome (SARS)-CoV-2 and other viruses and their potential indirect effects on the host by avoiding exaggerated immune responses (reduced cytokine release, Toll-like receptor response, antigen presentation related to lysosomal processing).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Currently, there is a large debate on the use of antimalarials for prophylaxis and treatment of SARS-CoV-2-induced disease based on preclinical in-vitro data, small case series and extrapolation from earlier studies of their effect on intracellular pathogens, including many viruses. Hydroxychloroquine (HCQ) or chloroquine have not demonstrated robust efficacy in prior randomized controlled studies against several other viruses. In-vitro data indicate a reduced viral replication of SARS-CoV-2. Especially immunomodulatory effects of antimalarials might also contribute to a clinical efficacy. For SARS-CoV-2 various large studies will provide answers as to whether antimalarials have a place in prophylaxis or treatment of the acute virus infection with SARS-CoV-2 but compelling data are missing so far.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In-vitro data provide a theoretical framework for an efficacy of antimalarials in SARS-CoV-2-induced disease but clinical proof is currently missing.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000731","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T03:00:30Z","timestamp":1594868430000},"page":"449-457","source":"Crossref","is-referenced-by-count":6,"title":["Role for antimalarials in the management of COVID-19"],"prefix":"10.1097","volume":"32","author":[{"given":"Eva V.","family":"Schrezenmeier","sequence":"first","affiliation":[{"name":"Department of Medicine\/Nephrology and Medical Intensive Care, Charit\u00e9-Universit\u00e4tsmedizin Berlin"},{"name":"Berlin Institute of Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Nephrology and Medical Intensive Care, Charit\u00e9-Universit\u00e4tsmedizin Berlin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology, Charit\u00e9-Universit\u00e4tsmedizin Berlin"},{"name":"Deutsches Rheumaforschungszentrum Berlin (DRFZ), Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci Trends"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/M20-1223","article-title":"A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19","volume":"172","author":"Kim","year":"2020","journal-title":"Ann Intern Med"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/BOR.0000000000000084","article-title":"Update on infections and vaccinations in systemic lupus erythematosus and Sjogren's syndrome","volume":"26","author":"Pasoto","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1124\/pr.115.011247","article-title":"Pharmacology of heparin and related drugs","volume":"68","author":"Mulloy","year":"2016","journal-title":"Pharmacol Rev"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","article-title":"Structure analysis of the receptor binding of nCoV","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"e105114","DOI":"10.15252\/embj.20105114","article-title":"SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells","volume":"39","author":"Lukassen","year":"2020","journal-title":"EMBO J"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0041-008X(67)90089-0","article-title":"Tissue distribution of chloroquine, hydroxychloroquine, and desethylchloroquine in the rat","volume":"10","author":"McChesney","year":"1967","journal-title":"Toxicol Appl Pharmacol"},{"key":"R12-20230829","first-page":"ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.devcel.2015.03.002","article-title":"CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature","volume":"33","author":"Miller","year":"2015","journal-title":"Dev Cell"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","article-title":"Insights from nanomedicine into chloroquine efficacy against COVID-19","volume":"15","author":"Hu","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for (2019-nCoV) acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1128\/JVI.03398-14","article-title":"Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step","volume":"89","author":"Mingo","year":"2015","journal-title":"J Virol"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/ard.40.5.480","article-title":"Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis","volume":"40","author":"Dixon","year":"1981","journal-title":"Ann Rheum Dis"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bcp.2013.05.013","article-title":"Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis","volume":"86","author":"Yang","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"175","DOI":"10.55563\/clinexprheumatol\/r3k9l6","article-title":"COVID-19: the new challenge for rheumatologists","volume":"38","author":"Ferro","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.onehlt.2020.100131","article-title":"Coalition: advocacy for prospective clinical trials to test the postexposure potential of hydroxychloroquine against COVID-19","volume":"9","author":"Picot","year":"2020","journal-title":"One Health"},{"key":"R25-20230829","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2020.05.030","article-title":"Fatal arrhythmias: another reason why doctors remain cautious about chloroquine\/hydroxychloroquine for treating COVID-19","author":"Uzelac","year":"2020","journal-title":"Heart Rhythm"},{"key":"R26-20230829","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1105","article-title":"Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality","author":"Bonow","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R27-20230829","article-title":"Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review","author":"Fiehn","year":"2020","journal-title":"Z Rheumatol"},{"key":"R28-20230829","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"R29-20230829","article-title":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)","author":"Chen","year":"2020","journal-title":"J Zhejiang Univ"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"R31-20230829","article-title":"No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial","author":"Mahevas","year":"2020","journal-title":"medRxiv"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jac\/dkv018","article-title":"Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases","volume":"70","author":"Al-Bari","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/s41598-017-01365-4","article-title":"In-vivo efficacy of chloroquine to clear asymptomatic infections in Mozambican adults: a randomized, placebo-controlled trial with implications for elimination strategies","volume":"7","author":"Galatas","year":"2017","journal-title":"Sci Rep"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archinte.159.2.167","article-title":"Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine","volume":"159","author":"Raoult","year":"1999","journal-title":"Arch Intern Med"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra062477","article-title":"Whipple's disease","volume":"356","author":"Fenollar","year":"2007","journal-title":"N Engl J Med"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/microorganisms8010085","article-title":"The use of antimalarial drugs against viral infection","volume":"8","author":"D\u2019Alessandro","year":"2020","journal-title":"Microorganisms"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1473-3099(11)70092-5","article-title":"Use of chloroquine in viral diseases","volume":"11","author":"Savarino","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"e00293","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol Res Perspect"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"e0194868","DOI":"10.1371\/journal.pone.0194868","article-title":"MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells","volume":"13","author":"Cong","year":"2018","journal-title":"PLoS One"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/JVI.00128-13","article-title":"The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies","volume":"87","author":"Gierer","year":"2013","journal-title":"J Virol"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","article-title":"Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties","volume":"95","author":"Goldman","year":"2000","journal-title":"Blood"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0149-2918(96)80063-4","article-title":"Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine","volume":"18","author":"Chiang","year":"1996","journal-title":"Clin Ther"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0149-2918(97)80045-8","article-title":"Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1","volume":"19","author":"Sperber","year":"1997","journal-title":"Clin Ther"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0149-2918(95)80039-5","article-title":"Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1","volume":"17","author":"Sperber","year":"1995","journal-title":"Clin Ther"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2011-01-329060","article-title":"Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders","volume":"118","author":"Piconi","year":"2011","journal-title":"Blood"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1089\/aid.2015.0336","article-title":"The effect of chloroquine on immune activation and interferon signatures associated with HIV-1","volume":"32","author":"Jacobson","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/hiv.12171","article-title":"Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy","volume":"16","author":"Routy","year":"2015","journal-title":"HIV Med"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2012.6936","article-title":"Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial","volume":"308","author":"Paton","year":"2012","journal-title":"JAMA"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1743-422X-3-39","article-title":"In vitro inhibition of human influenza A virus replication by chloroquine","volume":"3","author":"Ooi","year":"2006","journal-title":"Virol J"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1743-422X-4-39","article-title":"Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses","volume":"4","author":"Di Trani","year":"2007","journal-title":"Virol J"},{"key":"R55-20230829","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/jmv.24135","article-title":"Chloroquine enhances replication of influenza A virus A\/WSN\/33 (H1N1) in dose-, time-, and MOI-dependent manners in human lung epithelial cells A549","volume":"87","author":"Wu","year":"2015","journal-title":"J Med Virol"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1473-3099(11)70065-2","article-title":"Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial","volume":"11","author":"Paton","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1371\/journal.pntd.0000785","article-title":"A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults","volume":"4","author":"Tricou","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S0074-02762013000500010","article-title":"Chloroquine use improves dengue-related symptoms","volume":"108","author":"Borges","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/vbz.2008.0049","article-title":"On chikungunya acute infection and chloroquine treatment","volume":"8","author":"De Lamballerie","year":"2008","journal-title":"Vector Borne Zoonotic Dis"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cbf.3182","article-title":"Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity","volume":"34","author":"Akpovwa","year":"2016","journal-title":"Cell Biochem Funct"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T07:04:30Z","timestamp":1693292670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000731","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}